This article contains wording that promotes the subject in a subjective manner without imparting real information.(January 2023) |
Bioconvergence is a multidisciplinary approach in life sciences that leverages the integration of biotechnology, engineering, and computers to address complex challenges. This method is used in diagnostic processes and the development of materials and pharmaceuticals. [1] In addition to healthcare, bioconvergence contributes to improvements in sectors such as agriculture, energy, food, security, and climate. [2] Research by McKinsey indicates that the majority of bioconvergence's impact will be felt outside the healthcare sector, in areas like agriculture, aquaculture, consumer products, novel materials, chemistry, and energy. McKinsey estimates that bioconvergence solutions currently under development could generate an economic impact of up to US$ 4 trillion annually within the next 10 to 20 years. [3]
Bioconvergence uses methods from disciplines such as biology, chemistry, physics, engineering, medicine, mathematics, agriculture, computational sciences and artificial intelligence (AI), in order to solve challenges across several sectors.
Bioconvergence technologies in healthcare may include translational medicine, enabling the extraction of hidden insights from massive data sets; neuromorphic computing, which seeks to emulate the biological neural structure of the brain to increase processing performance and energy efficiency; creation of digital twins for clinical trials; and biochips such as an "organ on a chip" (OOC). [4] Other implications of bioconvergence include new methods of using nanorobotics for drug delivery, regenerative medicine, diagnostics and biological sensors, optogenetics, bioelectronics, engineered "living" materials, and more. [5] According to Belén Garijo, CEO of Merck, bioconvergence can also bring about the potential of personalized medicine". [6]
Traditional agriculture relies on land, water, and a suitable climate. Proponents of bioconvergence research attest that its technologies could be used to grow food anywhere in labs and indoor vertical farms. [7]
Potential applications also include new ways to conduct breeding of animals and plants using molecular or genetic markers that are quicker than established selective-breeding methods; more precise tools for genetic engineering of plants; use of the microbiome of plants, soil, animals, and water to improve the quality and productivity of agricultural production; and the development of alternative proteins, including cultured meat, alternative eggs, and alternative milk. [3]
Bioconvergence could transform the natural resource sector through new ways of making and obtaining raw materials and fuels, as well as new manufacturing techniques. This could potentially ease pressure on natural resources. [7]
The term "bioconvergence" was used in 2005 to describe the integration of bio- and information-technologies into the healthcare industry. [8] Since 2020, it has gained wider recognition.
In April 2020, The European Investment Bank and the Israel Innovation Authority concluded a cooperation agreement to jointly pursue investments in the globally emerging domain of bioconvergence. [9]
In March 2021, the US National Intelligence Council (NIC), which bridges the United States Intelligence Community with policy makers in the US, published a research paper on the "Future of Biology", concluding that "During the next 20 years, a more multidisciplinary and data-intensive approach to life sciences will shift our understanding of and ability to manipulate living matter. These disciplines, combined with cognitive science, nanotechnology, physics, and others, are propelling new leaps in our understanding. It is anticipated that the collective application of these diverse technologies to the life sciences—known as bioconvergence— will accelerate discovery and predictability in biotech design and production." [10] [ excessive quote ]
In September 2021, CELLINK Life Sciences, a Swedish publicly traded company that commercialized the first bio-based ink in 2016, changed its group name to BICO Group, short for "bioconvergence." It is building a portfolio that blends biology, engineering and computer science technologies and considering acquisition opportunities in bioconvergence technology companies. [11]
In May 2022, Israel launched a 5-year national plan worth ₪ 435 million (US$ 127 million) to boost research and development in bioconvergence. [12] Also in May 2022, Ben-Gurion University of the Negev (BGU) and Soroka Medical Center announced a strategic collaboration for the development of novel technologies in the field of bioconvergence. [13]
In October 2022, Japan announced that it will establish a global center of bioconvergence innovation in the Okinawa Institute of Science and Technology. It will be supported by a grant from the Japan Science and Technology Agency JST Program on Open Innovation Platform for Academia-Industry Co-Creation. [14]
According to a McKinsey report on public policy and "Biological innovations for complex problems", the Israel Innovation Authority is "investing in bioconvergence technologies to ensure that professionals in biology, computer science, mathematics, engineering, and nanoscience work seamlessly together". [15] [ excessive quote ] The Israel Innovation Authority views bioconvergence as potentially "one of the next significant growth engines of Israeli high-tech". [16]
According to research company Grand View Research, the global bioconvergence market was valued at USD 110.9 billion in 2021 and is anticipated to expand at a compound annual growth rate (CAGR) of 7.4% from 2022 to 2030. The significant market growth can be attributed to the increasing elderly population and the accelerating stem cell technology for the fixing of injured cells, tissues, and organs. [2] A McKinsey report in 2020 suggests that a pipeline of over 400 scientifically feasible use cases are already visible, and that these applications alone could have direct economic impact of up to US$ 4 trillion per year over the next 10 to 20 years. [3]
Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services.
The Technion – Israel Institute of Technology is a public research university located in Haifa, Israel. Established in 1912 by Jews under the dominion of the Ottoman Empire, the Technion is the oldest university in the country.
Science and technology in Israel is one of the country's most developed sectors. Israel spent 4.3% of its gross domestic product (GDP) on civil research and development in 2015, the highest ratio in the world. In 2019, Israel was ranked the world's fifth most innovative country by the Bloomberg Innovation Index. It ranks thirteenth in the world for scientific output as measured by the number of scientific publications per million citizens. In 2014, Israel's share of scientific articles published worldwide (0.9%) was nine times higher than its share of the global population (0.1%).
Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 kms from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).
Biological engineering or bioengineering is the application of principles of biology and the tools of engineering to create usable, tangible, economically viable products. Biological engineering employs knowledge and expertise from a number of pure and applied sciences, such as mass and heat transfer, kinetics, biocatalysts, biomechanics, bioinformatics, separation and purification processes, bioreactor design, surface science, fluid mechanics, thermodynamics, and polymer science. It is used in the design of medical devices, diagnostic equipment, biocompatible materials, renewable energy, ecological engineering, agricultural engineering, process engineering and catalysis, and other areas that improve the living standards of societies.
Jeonbuk National University is one of ten Flagship Korean National Universities founded in 1947, located in Jeonju, South Korea. Jeonbuk National University has been ranked 551–560th in the world by QS Top Universities Ranking in 2023.
The Department of Biotechnology (DBT) is an Indian government department, under the Ministry of Science and Technology responsible for administrating development and commercialisation in the field of modern biology and biotechnology in India. It was set up in 1986.
The California Institute for Quantitative Biosciences (QB3) is a nonprofit research and technology commercialization institute affiliated with three University of California campuses in the San Francisco Bay Area: Berkeley, San Francisco, and Santa Cruz. QB3's domain is the quantitative biosciences: areas of biology in which advances are chiefly made by scientists applying techniques from physics, chemistry, engineering, and computer science.
China has seen double-digit growth in its biotechnology industry and has gone from being one of the slowest to one of the fastest nations in the adoption of new biotechnologies. The biotech sector is seen in China and internationally as a core area of national scientific and economic development. The main national biotech body in the country is the China National Center for Biotechnology Development. The CNCBD is an organization established on November 3, 1983, under the Ministry of Science and Technology with the approval of the State Council. CNCBD is the sole national center to coordinate and implement the national S&T program in Biotechnology and Health.
A biological patent is a patent on an invention in the field of biology that by law allows the patent holder to exclude others from making, using, selling, or importing the protected invention for a limited period of time. The scope and reach of biological patents vary among jurisdictions, and may include biological technology and products, genetically modified organisms and genetic material. The applicability of patents to substances and processes wholly or partially natural in origin is a subject of debate.
Ryan Bethencourt is an American scientist, entrepreneur, and biohacker best known for his work as co-founder and CEO of Wild Earth, Partner at Babel Ventures and cofounder and former Program Director at IndieBio, a biology accelerator and early stage seed fund. Bethencourt was head of life sciences at the XPRIZE foundation, a co-founder and CEO of Berkeley Biolabs, a biotech accelerator, and Halpin Neurosciences, an ALS therapeutics-focused biotech company. Bethencourt co-founded Counter Culture Labs, a citizen science nonprofit, and Sudo Room, a hacker space based in downtown Oakland, California.
Translational Health Science and Technology Institute (THSTI) is an institute of the Biotechnology Research and Innovation Council (BRIC), Department of Biotechnology, Ministry of Science and Technology, Government of India. It was set up in 2009 and is located in NCR Biotech Science Cluster, Faridabad. Envisioned by former secretary of DBT, Dr. M. K. Bhan, the institute was created to enable a faster transition of lab research to market. Prof. Ganesan Karthikeyan is the Executive Director of THSTI.
Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.
Marek Glezerman is an Israeli obstetrician and gynecologist, Professor Emeritus of Obstetrics and Gynecology, head of Gender and Sex Conscious Medicine and immediate past chair of the Ethics Committee at the Faculty of Medicine, Tel Aviv University. He is the founding president of The Israel Society for Gender and Sex Conscious Medicine and past president of the International Society of Gender Medicine. Glezerman is also a member of the Ministry of Health's National Council for Obstetrics and Gynecology, Genetics and Perinatology. Prof. Glezerman is internationally considered one of the pioneers of Gender and Sex Conscious Medicine.
Shenzhen International BT Leadership Summit is a biology-focused business conference. It is held each year in September. It is arranged by the Shenzhen Municipal People's Government. It is held at the Shenzhen Convention and Exhibition Center.
Varda Shalev is an Israeli medical researcher,a professor of medicine at the Tel Aviv University School of Public Health, and a primary care physician. She is also the co-founder and Chief Medical Officer of Alike. In 11.2022 she became a managing partner at Team8 foundry. Shalev sits on the Board of Directors of Teva Pharmaceutical since 2023.
Herald Scholarly Open Access is an Indian publisher of various academic journals. It has a postal address in Herndon, Virginia, United States, but is actually based in Hyderabad, India. Herald Scholarly Open Access has been included on Beall's List of potential predatory open-access publishers, and has faced other criticisms of its publishing practices.
BIOTECanada, previously the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms.